when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

1,228 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT824 Endpoints627 BioPharma Dive239 onclive165 Fierce Biotech91 BioSpace89 raps32 globenewswire health28 fda press

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology6

FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC
An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC
onclive · 2mo ago↗ source
STAT+: Administration report on most favored nation drug pricing raises new details — and questions
Administration report on most-favored nation drug pricing raises new details — and questions.
STAT · 2mo ago↗ source
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive · 2mo ago↗ source

page 42 of 50

21

Infectious Disease4

Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.

onclive · 2mo ago↗ source

STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review

Sanofi has asked the FDA to pull its type 1 diabetes drug out of Commissioner Marty Makary’s new speedy drug review program.

STAT · 2mo ago↗ source

Dr Sznol on Biomarkers of Response in Metastatic Melanoma

Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.

onclive · 2mo ago↗ source

Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline

Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.

BioPharma Dive · 2mo ago↗ source

Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery

The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.

onclive · 2mo ago↗ source

STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’

Color Health, which coordinates cancer screening, is moving into a gap it observed — obtaining and coordinating actual cancer care.

STAT · 2mo ago↗ source

Novo hikes guidance on Wegovy pill’s fast sales start

In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.

BioPharma Dive · 2mo ago↗ source

Why the FDA is authorizing fruit-flavored vapes

Marty Makary says he was "skeptical initially" about flavored vapes but that age-gating technology could limit their use.

STAT · 2mo ago↗ source

STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease

An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.

STAT · 2mo ago↗ source

Avalo shares spike on skin drug data; BioNTech to cut staff

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.

BioPharma Dive · 2mo ago↗ source

STAT+: When the path to good AI is littered with bad data

In this edition of AI Prognosis, Brittany Trang raises the question: What kind of health data would we need to train AI models to be useful in health care.

STAT · 2mo ago↗ source

ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

onclive · 2mo ago↗ source

STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price

Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news

STAT · 2mo ago↗ source

STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more

One of the most powerful pharmaceutical lobbying groups is launching a new seven-figure advertising blitz targeting a federal drug discount program

STAT · 2mo ago↗ source

Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management

Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.

onclive · 2mo ago↗ source

Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration

New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.

onclive · 2mo ago↗ source

Disease Assessment and Mutational Testing in Progressive CLL

Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.

onclive · 2mo ago↗ source

Clinical Scenario Presentation and Treatment Approach for Progressive Disease

Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.

onclive · 2mo ago↗ source

Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC

Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.

onclive · 2mo ago↗ source

Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026

SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.

onclive · 2mo ago↗ source

HHS tackles ‘overmedication’

The cruise ship hantavirus outbreak, 988 staffing problems, and more health news from Morning Rounds

STAT · 2mo ago↗ source

CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.

BioPharma Dive · 2mo ago↗ source